QGEN vs. RGEN, PCVX, TECH, EXEL, NBIX, RVMD, IBRX, HALO, CRSP, and KRYS
Should you be buying Qiagen stock or one of its competitors? The main competitors of Qiagen include Repligen (RGEN), Vaxcyte (PCVX), Bio-Techne (TECH), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Revolution Medicines (RVMD), ImmunityBio (IBRX), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), and Krystal Biotech (KRYS). These companies are all part of the "biological products, except diagnostic" industry.
Qiagen (NYSE:QGEN) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, community ranking, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.
In the previous week, Qiagen had 3 more articles in the media than Repligen. MarketBeat recorded 7 mentions for Qiagen and 4 mentions for Repligen. Repligen's average media sentiment score of 1.05 beat Qiagen's score of 0.80 indicating that Repligen is being referred to more favorably in the news media.
Qiagen presently has a consensus price target of $50.95, suggesting a potential upside of 11.50%. Repligen has a consensus price target of $197.75, suggesting a potential upside of 15.01%. Given Repligen's stronger consensus rating and higher probable upside, analysts clearly believe Repligen is more favorable than Qiagen.
Repligen received 156 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 68.08% of users gave Repligen an outperform vote while only 60.79% of users gave Qiagen an outperform vote.
70.0% of Qiagen shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 9.0% of Qiagen shares are held by insiders. Comparatively, 1.2% of Repligen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Qiagen has higher revenue and earnings than Repligen. Qiagen is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.
Qiagen has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500. Comparatively, Repligen has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500.
Qiagen has a net margin of 17.38% compared to Repligen's net margin of 2.44%. Qiagen's return on equity of 12.59% beat Repligen's return on equity.
Summary
Repligen beats Qiagen on 10 of the 18 factors compared between the two stocks.
Get Qiagen News Delivered to You Automatically
Sign up to receive the latest news and ratings for QGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
